• Anneli Ahovuo-Saloranta, Ulla-Maija Rautakorpi, Oleg V Borisenko, Helena Liira, John W Williams, and Marjukka Mäkelä.
• Finnish Office for Health Technology Assessment (FinOHTA), National Institute for Health and Welfare (THL), Finn-Medi 3, Biokatu 10, Tampere, Finland, FI-33520.
• Cochrane Db Syst Rev. 2015 Oct 16; 2015 (10): CD000243CD000243.

AbstractCurrently, two separate Cochrane reviews, ‘Antibiotics for acute maxillary sinusitis in adults’ and ‘Antibiotics for clinically diagnosed acute rhinosinusitis in adults’ describe the effect of antibiotics for acute rhinosinusitis. Although both Cochrane reviews study the same condition, they look at different populations (patients in which the diagnosis was based on clinical signs and symptoms and patients in which the diagnosis was confirmed by imaging). Because of this, the conclusions are different in these Cochrane reviews. This was confusing for clinicians who needed to read both Cochrane reviews to know which conclusions are most applicable to their patients.
 
 This review is being withdrawn and will be incorporated into the updated publication of ‘Antibiotics for clinically diagnosed acute rhinosinusitis in adults’. This ‘merged’ review will still maintain the relevant distinction between the two populations. However, information on the effectiveness of antibiotics for rhinosinusitis will be published in the ‘merged’ Cochrane review. We will omit the comparison between antibiotics (as published in this Cochrane review) because the choice for certain antibiotics and/or doses differs according to the local antibiotic resistance patterns and therefore this comparison is less relevant. The editorial group responsible for this previously published document have withdrawn it from publication.

9 keywords...

hide…